Researchers have identified NIMA-related kinase 1 (NEK1) as a potential therapeutic target driving tumor growth. It was identified using Turbine Ltd.’s Simulated Cell platform when they simulated perturbations in the DNA damage response pathways. NEK1 is involved in DNA damage response, cell cycle and mitosis.
Researchers from Nanjing Medical University presented data from a study that aimed to investigate the role of amphiregulin (AREG) in activating intestinal fibroblasts and driving fibrogenesis.
Scientists from the University of Bern have reported preclinical data on KiH_E07_79, a designed ankyrin repeat protein (DARPin) consisting of an Fc fusion construct comprising E07, an immunoglobulin E (IgE)-binding protein, and E2_79, an IgE disruptive domain, fused to an IgG Fc domain via a GS-rich linker.
Kling Biotherapeutics BV has presented preclinical data on an antibody, KBA-1413, which recognizes a specific glycoform of CD43 that is shared among acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and solid tumor cells.
The standard therapy for moderate to severe cases of ulcerative colitis (UC) is treatment with infliximab, but it is estimated that about 40% of patients with UC do not respond to it. An international team of investigators set out to study the causes behind this, which are not clearly understood.
Researchers from Sitryx Therapeutics Ltd. and affiliated organizations presented data from a study that aimed to assess the potential of selective salt-inducible kinase 2 (SIK2) inhibition as a therapeutic strategy for the treatment of ulcerative colitis.
Preventing the interaction between the cellular adhesion integrin α4β7 and endothelial ligand mucosal addressin cell-adhesion molecule-1 (MAdCAM-1) is a validated strategy for Crohn’s disease and ulcerative colitis treatment. Paragon Therapeutics Inc. and Spyre Therapeutics Inc. have reported preclinical efficacy data on SPY-001, a long-acting monoclonal antibody targeting integrin α4β7.
Researchers from Paragon Therapeutics Inc. and Spyre Therapeutics Inc. have reported preclinical data for SPY-002, a novel extended half-life, fully human IgG1 monoclonal antibody (MAb) targeting tumor necrosis factor (TNF)-like ligand 1A (TL1A), being developed for the treatment of inflammatory bowel disease (IBD).
Jasper Therapeutics Inc. has presented data at the AAAAI 2024 conference regarding its CD117-targeting antibody briquilimab and its potential use in allergy and CD117-triggered anaphylactic reactions.
RSS
